CD8A and neoplasm: Cancer-inhibitory immune cells, including activated dendritic cells (aDCs), CD8+ T cells, macrophages, tumor cell infiltrating lymphocytes (TILs) and T regulatory cells (Tregs), were significantly higher in the high-risk group, suggesting a stronger anti-tumor immune response in these patients.